Transcatheter aortic valve replacement (TAVR) is standard of care for severe, symptomatic aortic stenosis. Real-world TAVR data collection contributes to benefit/risk, and safety evidence for the U.S. Food and Drug Administration, quality evaluation for the Centers for Medicare and Medicaid Services and hospitals, as well as clinical research and real-world implementation through appropriate use criteria.

Editors

JACC: Cardiovascular Interventions Editor-in-Chief

David J. Moliterno, MD, FACC

JACC: Cardiovascular Interventions CME/MOC/ECME Editor

Michael C. McDaniel, MD

Authors

Matheus Simonato, MD
Sreekanth Vemulapalli, MD
Mitchell Krucoff, MD

Important Dates

Date of Release: April 4, 2022
Term of Approval/Date of CME/MOC/ECME Expiration: April 3, 2023